LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Novo Nordisk A-S

Suletud

SektorTervishoid

67.74 0.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

67.19

Max

68.3

Põhinäitajad

By Trading Economics

Sissetulek

804M

29B

Müük

-7.6B

78B

P/E

Sektori keskmine

19.207

50.291

Aktsiakasum

6.53

Dividenditootlus

2.32

Kasumimarginaal

37.182

Töötajad

77,406

EBITDA

5.9B

46B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+40.74% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.32%

2.40%

Turustatistika

By TradingEconomics

Turukapital

43B

309B

Eelmine avamishind

67.13

Eelmine sulgemishind

67.74

Uudiste sentiment

By Acuity

80%

20%

359 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. mai 2025, 11:36 UTC

Peamised uudised

Novo Nordisk CEO to Step Down Amid Market Challenges

12. mai 2025, 09:36 UTC

Suurimad hinnamuutused turgudel

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7. mai 2025, 11:29 UTC

Peamised uudised
Tulu
Suurimad hinnamuutused turgudel

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

24. juuni 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23. juuni 2025, 13:09 UTC

Market Talk

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20. juuni 2025, 13:31 UTC

Omandamised, ülevõtmised, äriostud

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13. juuni 2025, 11:39 UTC

Market Talk

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13. juuni 2025, 10:04 UTC

Market Talk

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11. juuni 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10. juuni 2025, 13:38 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9. juuni 2025, 10:09 UTC

Market Talk

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3. juuni 2025, 15:03 UTC

Omandamised, ülevõtmised, äriostud

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29. mai 2025, 01:00 UTC

Peamised uudised

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20. mai 2025, 14:08 UTC

Tulu

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20. mai 2025, 07:43 UTC

Market Talk

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16. mai 2025, 18:35 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. mai 2025, 17:34 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16. mai 2025, 13:42 UTC

Kuumad aktsiad

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16. mai 2025, 13:27 UTC

Market Talk

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16. mai 2025, 13:15 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16. mai 2025, 12:17 UTC

Tulu

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7. mai 2025, 15:13 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7. mai 2025, 13:56 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. mai 2025, 13:45 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7. mai 2025, 11:25 UTC

Tulu

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7. mai 2025, 11:18 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

40.74% tõus

12 kuu keskmine prognoos

Keskmine 94.79 USD  40.74%

Kõrge 142.564 USD

Madal 61 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

4

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

62.63 / 69.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

359 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.